Nu-Med Plus (NUMD) Cash & Equivalents Growth (3y) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -9.44% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 19.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -36.69% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 36.60% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 40.99% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 34.11% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.52% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -0.70% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 28.25% |
| 10 | Nu-Med Plus | - | - | - | -79.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79.18% |
| Sep 30, 2025 | 45.84% |
| Mar 31, 2025 | -2.20% |
| Dec 31, 2024 | -41.20% |
| Sep 30, 2024 | -49.75% |
| Jun 30, 2024 | -61.86% |
| Mar 31, 2024 | -64.26% |
| Dec 31, 2023 | -66.95% |
| Sep 30, 2023 | -29.39% |
| Jun 30, 2023 | 69.92% |
| Mar 31, 2023 | 42.49% |
| Dec 31, 2022 | 117.86% |
| Sep 30, 2022 | -75.33% |
| Mar 31, 2022 | -52.23% |
| Dec 31, 2021 | -58.85% |
| Sep 30, 2021 | -42.59% |
| Jun 30, 2021 | -36.79% |
| Mar 31, 2021 | -20.33% |
| Dec 31, 2020 | -18.72% |
| Sep 30, 2020 | -57.47% |
| Jun 30, 2020 | -71.49% |
| Mar 31, 2020 | -61.27% |
| Dec 31, 2019 | -17.15% |
| Sep 30, 2019 | 211.59% |
| Jun 30, 2019 | -25.43% |
| Mar 31, 2019 | -35.72% |
| Dec 31, 2018 | 75.66% |
| Sep 30, 2018 | 827.33% |
| Jun 30, 2018 | 199.75% |
| Mar 31, 2018 | 176.84% |
| Dec 31, 2017 | 84.09% |
| Sep 30, 2017 | 93.76% |
| Jun 30, 2017 | 88.46% |
| Mar 31, 2017 | 244.02% |
| Dec 31, 2016 | -2.00% |
| Sep 30, 2016 | -45.06% |
| Jun 30, 2016 | 66.13% |
| Mar 31, 2016 | 186.78% |
| Dec 31, 2015 | 248.36% |
| Sep 30, 2015 | 4.48% |
| Jun 30, 2015 | -14.19% |
| Mar 31, 2015 | -39.61% |
| Dec 31, 2014 | 301.41% |